Identifying SARS-CoV-2 Entry Inhibitors Through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles

    July 2020 in “ bioRxiv (Cold Spring Harbor Laboratory) ”
    Catherine Z. Chen, Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer D. Petersen, Marco R. Straus, Wei Zhu, Paul Shinn, Hui Guo, Min Shen, Carleen Klumpp‐Thomas, Sam Michael, Joshua Zimmerberg, Wei Zheng, Gary R. Whittaker
    Studysummary This study identified six approved drugs that inhibited spike-mediated cell entry, potentially offering effective treatments against the initial stage of SARS-CoV-2 infection.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study identified six compounds—cepharanthine, abemaciclib, osimertinib, trimipramine, colforsin, and ingenol—as broad-spectrum inhibitors of spike-mediated entry of SARS-CoV-2, SARS-S, and MERS-S pseudotyped particles. These findings were based on a high throughput screen of an approved drugs library. The research aimed to contribute to the development of effective treatments against the initial stage of viral infection, potentially reducing the viral burden in COVID-19 patients. The authors declared no competing interests, and the work was supported by various institutions and foundations.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results